Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs

被引:34
作者
Morgan, C. Ll. [2 ]
Jenkins-Jones, S. [2 ]
Evans, M. [3 ]
Barnett, A. H. [4 ]
Poole, C. D. [2 ]
Currie, C. J. [1 ]
机构
[1] Cardiff Univ, Cardiff MediCtr, Sch Med, Dept Primary Care & Publ Hlth, Cardiff CF14 4UJ, S Glam, Wales
[2] Pharmatelligence, Dept Epidemiol, Cardiff, S Glam, Wales
[3] Univ Hosp Llandough, Dept Med, Cardiff, S Glam, Wales
[4] Univ Birmingham, Sch Med, Div Clin & Expt Med, Birmingham B15 2TT, W Midlands, England
基金
英国工程与自然科学研究理事会; 英国医学研究理事会;
关键词
antidiabetic drugs; obesity; secular trends; type; 2; diabetes; weight change; GLYCEMIC CONTROL; CARE; PREVALENCE; MELLITUS; PATTERNS; INSULIN; UK;
D O I
10.1111/j.1463-1326.2011.01552.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: This study aimed to describe the pattern of weight change in people with type 2 diabetes (T2DM) over time and when using alternative treatment regimens. Methods: Data were from routine clinical practice in the UK. The weight trend was determined for each year from 1995 to 2010 for both prevalent and incident cases. Baseline weight was compared to absolute (mean Delta) and relative weights (% Delta) at 6, 12 and 24 months. Results: Mean, standardized weight in prevalent cases increased from 83.4 to 92.1 kg for males and from 73.5 to 79.9 kg for females between 1995 and 2010 (p < 0.0001). For incident cases, the respective figures were 86.7 to 93.6 kg for males and 76.0 to 80.7 kg for females (p < 0.001). Between baseline and 6, 12 and 24 months, there were significant changes in weight for the majority of the treatment regimens selected for analysis. The largest weight increase at 12 months was for the patients who were prescribed a combination therapy with insulin and a thiazolidinedione, with a median increase of 4.1 kg (95% CI -0.60 to 8.0, p < 0.001). The largest weight decrease at 12 months was for the patients who were prescribed a combination therapy of metformin and exenatide, with a median decrease of -7.0 kg (95% CI -12.0 to -2.0, p < 0.001). Conclusions: There was a continual increase in body weight in people with T2DM over time, and considerable differences in the impact on weight using alternative treatment regimens. At the same time, glycaemic control remained relatively unchanged.
引用
收藏
页码:424 / 432
页数:9
相关论文
共 25 条
[1]   The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death - A population-based study of 13000 men and women with 20 years of follow-up [J].
Almdal, T ;
Scharling, H ;
Jensen, JS ;
Vestergaard, H .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (13) :1422-1426
[2]  
[Anonymous], HLTH SURV ENGL 2008
[3]   Secondary Failure of Metformin Monotherapy in Clinical Practice [J].
Brown, Jonathan B. ;
Conner, Christopher ;
Nichols, Gregory A. .
DIABETES CARE, 2010, 33 (03) :501-506
[4]  
Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P1066
[5]   Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008* [J].
Currie, C. J. ;
Peters, J. R. ;
Evans, M. .
DIABETIC MEDICINE, 2010, 27 (07) :744-752
[6]   Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study [J].
Currie, Craig J. ;
Peters, John R. ;
Tynan, Aodan ;
Evans, Marc ;
Heine, Robert J. ;
Bracco, Oswaldo L. ;
Zagar, Tony ;
Poole, Chris D. .
LANCET, 2010, 375 (9713) :481-489
[7]   Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [J].
DeFronzo, RA ;
Ratner, RE ;
Han, J ;
Kim, DD ;
Fineman, MS ;
Baron, AD .
DIABETES CARE, 2005, 28 (05) :1092-1100
[8]   The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].
Drucker, Daniel J. ;
Nauck, Michael A. .
LANCET, 2006, 368 (9548) :1696-1705
[9]   Prevalence and Trends in Obesity Among US Adults, 1999-2008 [J].
Flegal, Katherine M. ;
Carroll, Margaret D. ;
Ogden, Cynthia L. ;
Curtin, Lester R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (03) :235-241
[10]  
Gavin JR, 1999, DIABETES CARE, V22, pS5